Vaccines for Children program (United States, 1989 to 2026)

After a measles resurgence from 1989 to 1991 in which cost was a main reason children went unvaccinated, Congress made vaccines free to eligible children in 1993; the program is credited with high coverage, but its benefits are modeled for all routine vaccination, its oversight has had gaps, and its coverage list now depends on an advisory committee that few families follow.

The record

The problem before the program

• In 1989 the United States reported a provisional 17,850 measles cases, up 423 percent from 3,411 in 1988. That was the most in a year since 1978. There were 41 measles deaths, the most in a year since 1971. Four states (Illinois, Texas, California, Ohio) reported 67.9 percent of cases. About 59.7 percent of 1989 patients were unvaccinated or inadequately vaccinated. (CDC, MMWR, June 1, 1990, "Measles -- United States, 1989 and First 20 Weeks 1990"; opened)
• The same report said the rise "primarily reflected the increasing number of cases reported among unvaccinated inner-city preschool-aged children." Large preschool outbreaks hit Los Angeles, Chicago and Houston in 1989, and Dallas had about 2,900 confirmed and suspected cases in 1990. CDC said high-incidence areas may have had two to three times more cases than were officially reported. (MMWR 1990)
• CDC's program page says more than half of children with measles in the 1989 to 1991 epidemic were unvaccinated and that cost was a primary reason. (CDC, About the Vaccines for Children Program; opened)
• Earlier steps set the stage. The National Childhood Vaccine Injury Act of 1986 created a no-fault compensation system after a liability crisis. Georgetown's Center for Children and Families says that in the late 1980s budget cuts, uninsured children and liability worries pushed rates down, with a 1987 Children's Defense Fund report and a March 1988 Senate hearing on funding shortfalls. (Georgetown CCF, Oct. 2025; opened)

What the law does

• Congress created VFC in the Omnibus Budget Reconciliation Act, passed August 10, 1993. It became operational October 1, 1994, and is codified at Section 1928 of the Social Security Act (42 U.S.C. 1396s). It is an entitlement, not a yearly grant. (CDC program page)
• A "federally vaccine-eligible child" is a Medicaid-eligible child, an uninsured child, an American Indian or Alaska Native child, or a child with insurance that does not cover the vaccine who is served at a federally qualified health center or rural health clinic (the "underinsured" group). (42 U.S.C. 1396s, Cornell LII copy; opened. This is a mirror of the statute, not the Government Publishing Office text.)
• Providers may not charge for the vaccine itself. They may charge an administration fee, capped for eligible children at actual regional costs set by the Secretary, and may not refuse a child because the parent cannot pay that fee. (42 U.S.C. 1396s)
• The vaccines covered are those on the list set by the Advisory Committee on Immunization Practices (ACIP), acting through the CDC Director. Providers must follow the ACIP schedule unless medical judgment says otherwise. (42 U.S.C. 1396s)
• CDC negotiates contracts with manufacturers. The statute requires a supply reserve of 6 months beyond normal need and caps prices for vaccines under contract in May 1993 at the earlier price plus inflation. New vaccines are not bound by that cap. (42 U.S.C. 1396s)
• Money is approved through the Office of Management and Budget, flows through the Centers for Medicare and Medicaid Services to CDC, and vaccines are distributed through 63 state, local and territorial immunization programs. (CDC program page)

Timeline

Reach and results

• CDC's 2024 analysis covers 30 birth cohorts (1994 to 2023), about 117 million children, and nine routine vaccines. It estimates about 508 million illnesses, 32 million hospitalizations and about 1,129,000 deaths prevented, with $240 billion in direct immunization cost and $268 billion in societal cost. (CDC, MMWR 73(31), Aug. 2024; opened)
• The same analysis reports net savings of $540 billion (payer view) and $2.7 trillion (societal view), and benefit-cost ratios of 3.3 and 10.9. The "about $11 per $1" line is the societal gross ratio. (MMWR 2024)
• About 54 percent of children aged 18 or younger were VFC-eligible in 2023, and VFC bought roughly half of childhood vaccine doses at discounted prices (2022 market share data cited in MMWR 2024).
• An earlier CDC estimate for the 1994 to 2013 cohorts (78.6 million children) was about 322 million illnesses, 21 million hospitalizations and 732,000 premature deaths prevented. That report says one-dose measles coverage has been above 90 percent since 1996, up from under 70 percent before the outbreak. (CDC, MMWR 63(16), April 2014; opened)

Disputed or differing numbers

| Item | Figure A | Figure B | Notes | |---|---|---| | Measles cases in the epidemic | More than 55,000 (CDC 2014 report; Georgetown CCF; Wikipedia) | 17,850 provisional for 1989 alone (MMWR 1990) | Different periods: the 55,000 spans 1989 to 1991, the 17,850 is one year, provisional | | Measles deaths | 123 (Wikipedia, 1989 to 1991) | 41 for 1989 (MMWR 1990) | Wikipedia's 123 was not checked against a CDC source | | Prevented deaths | About 732,000 (1994 to 2013 cohorts) | About 1,129,000 (1994 to 2023 cohorts) | Different cohorts and methods; both modeled | | Share of vaccines bought by VFC | About 52 to 55 percent (Wikipedia) | "Roughly one half" (MMWR 2024) | Consistent within rounding | | Eligible children, 2010 | About 40 million children (CIDRAP) | 54 percent of children 18 or younger, 2023 (MMWR 2024) | Different years, not directly comparable |

Problems and costs on the record

• A 2012 HHS Office of Inspector General review of 45 providers (from five large grantees: California, Florida, Georgia, New York City, Texas) found 76 percent stored vaccine at inappropriate temperatures for at least 5 cumulative hours in a two-week period. Thirteen of 45 kept expired vaccine next to good vaccine. CDC agreed with all four recommendations. (CIDRAP summary of the OIG report; opened. The OIG report itself, listed as A-09 series, was not opened.)
• A 2023 OIG audit (A-09-22-01000, Sept. 8, 2023) covered 39,120 providers for July 2020 to June 2021. Recipients did not conduct compliance site visits on time at 11,499 (29 percent), did not verify follow-up on 33,316 of 127,594 issues (26 percent), and did no storage visits at the two CDC-approved depots. OIG cited staffing, COVID-19 priorities, no written CDC oversight procedures, and no reminders in the tracking system. CDC concurred; all four recommendations are listed as closed in 2024. (HHS OIG; opened)
• Coverage gaps remain by insurance status. For children born 2017 to 2018, coverage by 24 months for the combined 7-vaccine series was 78.3 percent for the privately insured, 65.6 percent on Medicaid and 48.3 percent for the uninsured. The report does not break coverage out by VFC eligibility and notes parents may not know of the program. Household response was 22.5 percent. (CDC, MMWR 70(41), Oct. 2021; opened)
• A 1996 review by David Wood and Neal Halfon (Archives of Pediatrics and Adolescent Medicine) said VFC's effect on access would be "uneven." It noted critics who argue vaccine cost is not a major barrier. (RAND listing; only the abstract page was opened.)
• Wikipedia says a few firms now make all U.S. childhood vaccines after price competition for large government contracts, and that disparities persist for newer vaccines such as hepatitis A, rotavirus and HPV. These are Wikipedia's claims and were not checked against a primary source. (Wikipedia; opened)

Recent ACIP actions touching VFC

• Because VFC covers what ACIP lists, committee votes change what is free. Trade press reports that in September 2025 ACIP voted for VFC coverage of a combined MMRV vaccine on one day, then voted 9 to 3 with three abstentions against it the next day, citing "confusion in the interpretation of the vote yesterday" (chair Martin Kulldorff). The votes needed approval by the acting CDC director. (Managed Healthcare Executive; opened)
• On December 5, 2025, ACIP voted 8 to 3 for "individual based decision making" on the hepatitis B birth dose for infants of mothers who test negative. A law-firm summary says the birth dose should remain available under VFC and that changes take effect only after CDC Director adoption. (Manatt; opened) We did not verify whether those votes were adopted.

What this case shows

1. A cost barrier was named in public data, then fixed by statute. CDC's own 1990 report showed the outbreak concentrated among unvaccinated inner-city preschoolers, and CDC later said cost was a primary reason. Congress answered with an entitlement in 1993. Ordinary people could see the problem in weekly public reports and vote on the fix. (MMWR 1990; CDC program page)
2. The program is built on who was left out. The eligibility test lists the groups who could not pay: Medicaid-enrolled, uninsured, American Indian and Alaska Native, and some underinsured children. It is a rare case where the excluded group is the statute's defined beneficiary. (42 U.S.C. 1396s)
3. The scale of the benefit is large but the credit is shared. CDC models roughly 1.1 million deaths prevented across 1994 to 2023 cohorts, but says it cannot attribute benefits to VFC alone because eligibility and purchasing shares change. A citizen reading "VFC saved" headlines needs the footnote. (MMWR 2024)
4. Who decides what is free is not always visible. The ACIP list sets VFC coverage. Votes on MMRV and hepatitis B in 2025 show a technical committee's recorded votes, sometimes reversed within a day, can change what a child gets without a cost to the family. Families can attend and comment, but few do. (Managed Healthcare Executive; Manatt)
5. Oversight lags the entitlement. Storage and site-visit gaps in 2012 and 2023 mean a free vaccine may be handled poorly, and the public learns this only from inspector general audits. (CIDRAP; HHS OIG)

The strongest objections, and our answers

1. Objection: The savings figures are advocacy numbers. They are CDC models with discounting at 3 percent, assumptions about how many cases would occur, and exclusion of some program costs. Mitigation: We cite the authors' own limits (federal, state and local management costs and excise taxes excluded; non-vaccine factors such as hygiene not modeled) and say the figures are for routine vaccination, not VFC alone. The 2014 report adds that factors other than immunization may have lowered diphtheria risk, so the model may overstate prevented burden.
2. Objection: Cost was not the main barrier, so the program may have been unnecessary. Wood and Halfon note critics holding this view. Mitigation: CDC reports that more than half of measles patients were unvaccinated and that cost was a primary reason, and coverage rose after 1994. But rising coverage also coincided with school requirements and other policies, and we do not claim VFC alone caused it. The 2021 data show gaps persist among Medicaid and uninsured children, which suggests cost is not the only barrier.
3. Objection: Government purchasing power hurt the vaccine market. Wikipedia reports a consolidated industry and price competition. Mitigation: Unverified against a primary source. We include the claim as a view, flagged as unverified, and note that the statute itself caps prices on older contracts and requires supply reserves.
4. Objection: The 2012 and 2023 audit findings are overblown, since no harm was shown. Mitigation: The audits measured process, not illness. They found missed visits and temperature excursions, not injured children. We report that CDC agreed with the recommendations and closed them, and that the 2023 lapses overlapped with COVID-19 priorities.
5. Objection: The 2025 ACIP votes are a partisan issue. Mitigation: The case does not score any party, official or committee. We state only the recorded votes and that adoption was not verified. The point for this project is that VFC coverage depends on a committee list.

Open questions: what would change our minds

• The 1993 statute text at govinfo and the legislative history were not opened; we used a Cornell copy of the codified section. Unverified against the original Public Law.
• The full OIG 2012 report was not opened; we relied on a CIDRAP summary. The 2023 OIG page was opened.
• Whether the 2025 ACIP votes on MMRV and hepatitis B were adopted, and their effect on VFC, was not verified.
• The Wood and Halfon (1996) full text was not read, so the criticism that cost is not a major barrier is known only from the abstract page.
• The count of 123 measles deaths for 1989 to 1991 (Wikipedia) was not matched to a CDC source.
• The claim that VFC caused the coverage rise would need a comparison study that isolates VFC from school mandates, Medicaid changes and the post-outbreak response; we did not find one.
• Annual federal VFC spending by year was not found. The only dollar figure is $3.6 billion for 2010 (via CIDRAP).
• Provider participation rates and out-of-pocket administration fees for eligible families were not checked.

Sources

Found an error or a better source? We keep every correction on the record with its date and reason. Nothing here is quietly rewritten.